Montrouge, France, February 10, 2023

DBV Technologies To Participate In Upcoming investor conference

DBV Technologies DBVTFa clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global Biopharma Conference, taking place February 13-16, 2023. Daniel Tassé, Chief Executive Officer, will deliver a company presentation on Thursday, February 16, 2023 as well as participate in one-on-one meetings with investors throughout the day.

A live webcast of the presentation will be available on the Investors & Media section of the company’s website: https://wsw.com/webcast/svb8/dbvt/1621296.

A replay will also be available on the DBV Technologies website for 90 days after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad application potential in immunotherapy. Based on Epicutaneous Immunotherapy or EPIT™, Viaskin is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the company is dedicated to safely transforming the care of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and North American offices in Basking Ridge, NJ. The company’s common shares are traded on the B segment of Euronext Paris DBVFR and the company’s ADSs (each representing one-half of a common share) trade on the Nasdaq Global Select Market DBVT.

investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.